Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Hutchinson China MedTech Limited has never downplayed the extent of its ambition to put Chinese drug development on the map, so clearly it has not held back with the hyperbole on announcing its upcoming global offering on the Stock Exchange of Hong Kong (SEHK). 15 April 2019
Biotechnology
Shareholders in New York drugmaker Bristol-Myers Squibb have voted to approve the proposed $74 billion merger with Celgene. 15 April 2019
Biotechnology
The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of 10 million euros ($11 million) to support late-stage trials for novel antimalarial combinations, including KAF156 (ganaplacide). 15 April 2019
Biotechnology
The US regulator has agreed to expand the monotherapy label for Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) in lung cancer. 12 April 2019
Biotechnology
Janssen has added the first two first data centers to a Europe-wide program to gain better real-world evidence (RWE) on blood cancers. 11 April 2019
Biotechnology
Promising early data on a combination treatment for non-alcoholic steatohepatitis (NASH) has been presented by Gilead Sciences at The International Liver Congress in Vienna. 11 April 2019
Biotechnology
Bowing to pricing pressure in the key US market, French pharma major Sanofi has said it will cap the cost of its insulin products at $99 per month for certain patients. 11 April 2019
Biotechnology
Shares of UK cell-based therapies company ReNeuron leapt as much as 30% after it said it has signed an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development, a subsidiary of Shanghai Fosun Pharmaceutical, for the development, manufacture and commercialization of ReNeuron’s CTX and hRPC cell therapy programs in the People’s Republic of China. 11 April 2019
Biotechnology
If Amgen and UCB’s expectations for big sales for their partnered asset Evenity (romosozumab) in postmenopausal osteoporis had long since faded, then Tuesday’s approval will likely have further dampened their optimism. 10 April 2019
Biotechnology
British biotech Kymab has appointed Simon Sturge as its new chief executive, effective 1 May 2019. Mr Sturge will replace David Chiswell, who has been in the role since 2015. 10 April 2019
Biotechnology
Hong Kong-listed WuXi Biologics and NBE-Therapeutics, a privately owned Swiss biotech have announced a comprehensive development and manufacturing partnership for NBE's first ADC lead product NBE-002 (anti-ROR1). 9 April 2019
Biotechnology
US biotech XOMA Corporation has agreed to acquire the rights to potential royalties and a portion of any milestone payments associated with five hematology assets from antithrombotic drugs specialist Aronora. 9 April 2019
Biotechnology
China’s biopharma start up Ascentage Pharma has entered into a strategic collaboration with Shanghai Junshi Biosciences to explore the synergies of Ascentage's inhibitor of apoptosis proteins (IAP) inhibitor APG-1387, and Junshi Biosciences' anti-PD-1 therapy toripalimab in clinical trials in solid and hematological tumors in China. 9 April 2019
Biotechnology
Shares in Japanese oncology specialist Oncolys Biopharma closed 18% up on Monday after the announcement of a deal with Chugai Pharmaceutical, part of Swiss pharma giant Roche. 8 April 2019
Biotechnology
Regeneron Pharmaceuticals has entered into a collaboration with fellow US biotech Alnylam Pharmaceutical to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. 8 April 2019
Biotechnology
China, Canada and the USA are all represented in a collaboration to jointly develop a therapy for neurologic disorders by harnessing the natural power of the immune system. 8 April 2019
Biotechnology
Shares in oncology specialist Merrimack Pharmaceuticals closed 16% down on Friday after the US company announced that it was discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of solid tumors. 8 April 2019
Biotechnology
The research phase of the RNAi therapeutics collaboration between Sanofi and Alnylam Pharmaceuticals is over, the companies have announced. 8 April 2019
Biotechnology
Japanese pharma major Eisai says that its in-house discovered fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor E7090 has been granted the Sakigake designation by Japan’s Ministry of Health, Labor and Welfare for the treatment of unresectable biliary tract cancer with FGFR2 gene fusion. 8 April 2019
Biotechnology
Chinese biotechs will seek more cross-border licensing deals in the coming years, especially for early-stage assets, said speakers at the annual China Healthcare Investment Conference (CHIC) held in late March in Shanghai. 8 April 2019
All news
Biotechnology
Belgium’s largest drugmaker UCB on Friday announced the successful closing of the sale, divestment and license of its mature neurology and allergy portfolio in China to CBC Group, Asia’s largest healthcare-focused asset management group, and Mubadala Investment Company for an enterprise value of $680 million, first announced earlier this year. 30 November 2024
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze